TY - CHAP M1 - Book, Section TI - Systemic Therapy of Urologic Tumors A1 - Koshkin, Vadim S. A1 - Small, Eric J. A2 - McAninch, Jack W. A2 - Lue, Tom F. PY - 2020 T2 - Smith & Tanagho's General Urology, 19e AB - The use of chemotherapy, targeted therapeutics, and more recently immunotherapy (see Chapter 25) in the treatment of malignant tumors of the genitourinary system serves as a paradigm for a multidisciplinary approach to cancer. The careful integration of surgical and systemic treatments has resulted in impressive advances in the management of urologic cancers. By definition, surgical interventions are directed at local management of urologic tumors, whereas chemotherapy and biologic therapy are systemic in nature. Although there is no question that there are times in the natural history of a genitourinary tumor when only one therapeutic method is required, a multidisciplinary approach is usually beneficial. This chapter details the importance of a joint surgical–medical approach to patients with urologic malignancies. A practicing urologist should collaborate closely with a medical oncologist and should feel comfortable speaking with patients about the uses, risks, and benefits of chemotherapy, and other forms of systemic therapy such as tyrosine kinase inhibitors (TKIs) or immunotherapy. The role of immunotherapy in the management of genitourinary tumors is covered in Chapter 25. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/29 UR - accesssurgery.mhmedical.com/content.aspx?aid=1171181029 ER -